Key takeaways
- • Frequency: Mild delayed emptying is universal (the mechanism); severe gastroparesis is uncommon.
- • Trial reference: FDA semaglutide label update 2023 (ileus) / ASA perioperative guidance 2023 (Severe: uncommon).
- • Management: Eat smaller, lower-fat, lower-fiber meals when symptoms flare — large fatty meals empty slowest
- • Call your prescriber if: Persistent vomiting or inability to keep food/liquids down
Why this happens
Activating GLP-1 receptors slows the muscular contractions that move food through the stomach and gut. For most people this is mild and intended (you feel full longer). Rarely it becomes severe or persistent, causing ongoing nausea, vomiting, and bloating. Risk is higher with rapid dose increases and in people with pre-existing motility disorders.
How to manage it
- Eat smaller, lower-fat, lower-fiber meals when symptoms flare — large fatty meals empty slowest
- Stay upright for 1-2 hours after eating; don’t lie down right after meals
- Sip fluids steadily to avoid dehydration if appetite is very low
- Ask your prescriber about slower titration or a temporary dose hold if symptoms are severe
- Tell your anesthesiologist you take a GLP-1 before any surgery or endoscopy — guidance is often to hold the dose first (aspiration risk)
- Report persistent vomiting early rather than pushing through it
GLP1Zoom doesn't prescribe — these are general management guidance from FDA labels and clinical trial reports. Personalized recommendations require your prescribing clinician.
When to call your doctor
Red flags — seek medical attention
- • Persistent vomiting or inability to keep food/liquids down
- • Severe bloating with abdominal distension, or no bowel movement/gas (possible ileus or obstruction — urgent)
- • Severe, persistent upper-abdominal pain
- • Signs of dehydration: dark urine, dizziness, rapid heartbeat
Drug-specific notes
- Wegovy/Ozempic: Semaglutide labeling updated in 2023 to add an ileus warning; report persistent severe GI symptoms to your prescriber
- All GLP-1s: All slow gastric emptying by design; current anesthesia guidance recommends holding GLP-1s before procedures
Frequently asked questions
Why does stomach paralysis (gastroparesis) happen on GLP-1 medications?
Activating GLP-1 receptors slows the muscular contractions that move food through the stomach and gut. For most people this is mild and intended (you feel full longer). Rarely it becomes severe or persistent, causing ongoing nausea, vomiting, and bloating. Risk is higher with rapid dose increases and in people with pre-existing motility disorders.
When should I call a doctor about stomach paralysis (gastroparesis)?
Persistent vomiting or inability to keep food/liquids down Severe bloating with abdominal distension, or no bowel movement/gas (possible ileus or obstruction — urgent) Severe, persistent upper-abdominal pain Signs of dehydration: dark urine, dizziness, rapid heartbeat
How common is stomach paralysis (gastroparesis) on GLP-1 medications?
Mild delayed emptying is universal (the mechanism); severe gastroparesis is uncommon
Other GLP-1 symptoms
Gastrointestinal
Nausea on GLP-1 medications
Gastrointestinal
Diarrhea on GLP-1 medications
Gastrointestinal
Constipation on GLP-1 medications
Systemic
Fatigue on GLP-1 medications
Neurological
Headache on GLP-1 medications
Skin / Hair
Hair loss on GLP-1 medications
Symptom management is general guidance based on FDA-approved prescribing information. Always discuss specifics with your prescribing clinician. In medical emergencies, call 911 or go to the nearest emergency department. Full disclaimer.
References
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly for Treatment of Obesity (Jastreboff et al., NEJM)(2022)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms and Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide in Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes in T2D (Marso et al., NEJM)(2016)